- Home
- SJT vs CRBU Comparison
SJT vs CRBU Comparison
Compare SJT & CRBU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SJT | CRBU |
|---|---|---|
| Founded | 1980 | 2011 |
| Country | United States | United States |
| Employees | 495 | N/A |
| Industry | Oil & Gas Production | Medicinal Chemicals and Botanical Products |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 139.8M | 145.8M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | SJT | CRBU |
|---|---|---|
| Price | $2.67 | $1.67 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $10.75 |
| AVG Volume (30 Days) | 201.9K | ★ 1.3M |
| Earning Date | 05-14-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.64 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $1.63 |
| Revenue Next Year | N/A | $10.93 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.37 | $1.38 |
| 52 Week High | $6.61 | $3.53 |
Technical Indicators
Market Signals| Indicator | SJT | CRBU |
|---|---|---|
| Relative Strength Index (RSI) | 45.72 | 51.00 |
| Support Level | $2.57 | $1.40 |
| Resistance Level | $2.79 | $1.77 |
| Average True Range (ATR) | 0.11 | 0.07 |
| MACD | 0.04 | 0.02 |
| Stochastic Oscillator | 83.33 | 92.16 |
Price Performance
Historical ComparisonAbout SJT San Juan Basin Royalty Trust
San Juan Basin Royalty Trust is an energy sector royalty trust in the United States. It owns approximately 75% net profit interest in a large number of natural gas properties in the San Juan Basin of New Mexico. About 98% of the royalties San Juan collects come from natural gas, with the balance coming from oil.
About CRBU Caribou Biosciences Inc.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company is focused on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic malignancies: Vispacabtagene regedleucel and CB-011. It operates in one reportable segment, which is the business of developing allogeneic CAR-T cell therapies. Geographically, it operates in the United States and the rest of the World, of which the United States derives the maximum revenue.